In Section C, members will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until finally disorder progression or perhaps the members are not able to tolerate the study drugs. 88 These preclinical studies offer paradigms for long term clinical trials https://remingtontqnmi.estate-blog.com/31282051/top-latest-five-brd4-targeted-therapy-abbv-744-clinical-data-urban-news